Medical lens company STAAR Surgical (NASDAQ: STAA) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 12% year on year to $83.41 million. Its GAAP profit of $0.11 per share was significantly above analysts’ consensus estimates.

Is now the time to buy STAA? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

STAAR Surgical’s third quarter was marked by a favorable market reaction after revenue and profits exceeded Wall Street’s expectations, even as headline sales declined year over year. Management attributed the results to robust demand for its EVO+ and toric lenses, particularly in China, where product mix and pricing powered growth despite supply constraints. CEO Warren Foust noted the company’s progress in shifting manufacturing to Switzerland, which helped mitigate tariff impacts and improve supply chain resilience. The company also highlighted broader adoption across mid-tier hospitals and sustained expansion in key international markets.

Looking forward, STAAR Surgical’s outlook is shaped by efforts to scale manufacturing, continued innovation, and commercial execution. Management expects gross margins to improve as both U.S. and Swiss facilities ramp up to full capacity, and new product launches—especially first-in-human trials for presbyopia lenses—are anticipated in the coming months. CEO Warren Foust emphasized, “Our ambition is to build toward a meaningful product launch in a critical market every 18-24 months,” underscoring the focus on pipeline expansion and operational improvements to drive future growth.

Key insights from management’s remarks

Management cited product mix, manufacturing transitions, and evolving market dynamics as the primary factors influencing Q3 performance and the company’s strategic direction going forward.

• China market mix shift: Growth in China stemmed from increased demand for EVO+ and toric lenses, which command higher average selling prices. Management noted that all sales growth in China was due to product mix, as higher-value lenses offset supply constraints and inventory management efforts.
• Manufacturing transition completed: The shift of all China-bound lens manufacturing to Switzerland reduced tariff exposure and increased supply chain flexibility. This transition, alongside a new ERP system and an additional clean room in Switzerland, positions the company to meet future demand more effectively.
• International expansion: Outside China, STAAR Surgical saw notable growth in EMEA—driven by Spain, Germany, and the U.K.—and in the Americas, with particular momentum in the U.S. The company highlighted rising adoption at mid-tier and public hospitals, expanding its addressable market.
• Innovation pipeline advances: The company is preparing to launch first-in-human trials for two presbyopia lenses, reflecting a broader push to accelerate product development. Ben Park, the new Chief Technology Officer, is leading R&D efforts to expand the product portfolio beyond core ICL offerings.
• Operational improvements ongoing: Management is focused on boosting manufacturing yields, which could generate significant incremental profit per percentage point improvement. Upgrades in supply chain planning and inventory management are expected to support both financial discipline and future product availability.

Drivers of future performance

STAAR Surgical’s outlook centers on manufacturing scale-up, new product development, and ongoing expansion into new markets, balanced by market and operational risks.

• Manufacturing efficiency gains: Management expects gross margins to recover as Swiss and U.S. facilities reach full capacity, benefiting from yield improvements and reduced tariff exposure. These operational changes are intended to support long-term profitability and meet rising global demand.
• Product innovation and launches: Upcoming first-in-human trials for new presbyopia lenses and ongoing enhancements to the EVO+ platform are seen as critical growth drivers. Management aims to launch new products in key markets every 18-24 months, targeting both existing and newly eligible patient populations.
• Market expansion and adoption: Broader adoption in the U.S., EMEA, and mid-tier hospitals in China is expected to drive future revenue. However, management cautioned about possible headwinds in South Korea and highlighted the importance of targeted commercial efforts and education to sustain growth.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will monitor (1) the pace of manufacturing yield improvements and whether Swiss facility capacity meets rising demand, (2) progress on first-in-human trials for presbyopia lenses and any subsequent regulatory milestones, and (3) sustained growth in key regions outside China, especially in the U.S. and EMEA. Ongoing management of supply chain constraints and product mix will also be key indicators of execution.

STAAR Surgical currently trades at $31.13, up from $27.17 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.